Table 5.

Association Between CAV1 Variations and Metabolic Disorders

	rs926198					rs11773845
	β-Coefficient	OR	95% CI	Pa	P value (adjusted)b	β-Coefficient	OR	95% CI	Pa	P value (adjusted)b
Weight excess	−0.042	0.95	0.71–1.29	0.779	0.610	0.018	1.01	0.78–1.33	0.894	0.830
Abdominal obesity	−0.078	0.93	0.58–1.47	0.741	0.740	0.251	1.29	0.84–1.96	0.241	0.030
Hypertension	0.070	1.07	0.70–1.66	0.748	0.130	−0.202	0.81	0.54–1.23	0.337	0.940
Hyperglycemia	0.029	1.02	0.76–1.40	0.853	0.920	0.107	1.11	0.83–1.48	0.459	0.930
Hypertriglyceridemia	0.069	1.07	0.79–1.45	0.654	0.310	0.365	1.44	1.08–1.90	0.010	0.010
Low serum HDL-C	−0.106	0.90	0.67–1.21	0.486	0.550	0.072	1.07	0.82–1.41	0.606	0.600
Metabolic syndrome	−0.021	0.97	0.67–1.42	0.912	0.310	0.461	1.58	1.11–2.26	0.011	0.020

An additive model was assessed through a logistic regression where risk alleles were interpreted as the unit. Genetic variations in rs926198 (TT = 0, CT = 1, and CC = 2) and rs11773845 (CC = 0, AC = 1, and AA = 2) were included as independent variables. Age, sex, current treatment for dyslipidemia or diabetes, and BMI were included as confounding variables (BMI was not used for Weight Excess analysis, treatment for diabetes was not used for hyperglycemia assessment, and treatment for dyslipidemia was not used for high serum triglyceride analysis). An admixture-adjustment was performed through a Monte-Carlo-Markov Chain where a three hybrid genetic stratification was assumed.

^aP values <0.025 were considered as statistically significant (Bonferroni correction).

^bAdmixture adjustment with Monte-Carlo-Markov Chain (k = 3).

CI, confidence interval; OR, odds ratio.

Statistically significant values are highlighted in bold.